Displaying 13 - 24 of 31
Metabolism, Alcohol & Toxicity
3

Novo Nordisk: Navigating MASH patient care - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Displaying 13 - 24 of 31